These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 7878284)
1. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias]. Carmena R Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284 [No Abstract] [Full Text] [Related]
2. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related]
3. [Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia]. MartÃnez-Castelao A Med Clin (Barc); 1995 Nov; 105(18):719. PubMed ID: 8538262 [No Abstract] [Full Text] [Related]
4. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering. Hughes AD J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
6. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Pedersen TR; Tobert JA Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485 [TBL] [Abstract][Full Text] [Related]
7. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias. Aronson JK; Ng LL Q J Med; 1990 Feb; 74(274):111-5. PubMed ID: 2111916 [No Abstract] [Full Text] [Related]
8. Variable influence of statins on isoprostanes in hyperlipidemia. Sinzinger H; Oguogho A Adv Exp Med Biol; 2003; 525():209-12. PubMed ID: 12751770 [No Abstract] [Full Text] [Related]
9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
10. [Simvastatin]. Burgmer U; Mohr K Dtsch Med Wochenschr; 1996 Jun; 121(23):769-70. PubMed ID: 8646995 [No Abstract] [Full Text] [Related]
11. Fluvastatin for lowering cholesterol. Med Lett Drugs Ther; 1994 May; 36(923):45-6. PubMed ID: 8177137 [No Abstract] [Full Text] [Related]
12. Toward a role for statins in immunomodulation. Mach F Mol Interv; 2002 Dec; 2(8):478-80. PubMed ID: 14993398 [TBL] [Abstract][Full Text] [Related]
13. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Garnett WR Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826 [TBL] [Abstract][Full Text] [Related]
14. The beneficial effects of HMG-coenzyme A reductase inhibitor in the primary and secondary prevention of atherosclerosis in the coronaries. Drown DJ Prog Cardiovasc Nurs; 1996; 11(2):38-9. PubMed ID: 8718962 [No Abstract] [Full Text] [Related]
15. Statins do more than just lower cholesterol. Vaughan CJ; Murphy MB; Buckley BM Lancet; 1996 Oct; 348(9034):1079-82. PubMed ID: 8874463 [No Abstract] [Full Text] [Related]